Research programme: high mobility group box chromosomal protein-1 inhibitors - Nautilus/Sienna Biopharmaceuticals

Drug Profile

Research programme: high mobility group box chromosomal protein-1 inhibitors - Nautilus/Sienna Biopharmaceuticals

Alternative Names: CT500 variant - Nautilus/Sienna Biopharmaceuticals; HMGB-1 inhibitors - Nautilus/Sienna Biopharmaceuticals; Improved CT500

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Creabilis Therapeutics; Nautilus Biotech
  • Class Proteins
  • Mechanism of Action Cytokine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Rheumatoid arthritis; Sepsis

Most Recent Events

  • 06 Dec 2016 Creabilis Therapeutics has been acquired by Sienna Biopharmaceuticals
  • 29 Nov 2006 Preclinical data added to the pharmacodynamics section
  • 08 Sep 2004 Preclinical trials in Rheumatoid arthritis in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top